Predicting and preventing adverse drug reactions in the very old

被引:93
|
作者
Merle, L [1 ]
Laroche, ML
Dantoine, T
Charmes, JP
机构
[1] CHU Dupuytren, Ctr Reg Pharmacovigilance, Serv Pharmacol Toxicol, F-87042 Limoges, France
[2] CHU Dupuytren, Dept Gerontol Clin, Limoges, France
关键词
D O I
10.2165/00002512-200522050-00003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The size of the elderly population has been increasing steadily for several years. Individuals in this age group often have several concomitant diseases that require treatment with multiple medications. These drugs, for various reasons and especially as a consequence of potential accumulation, may be associated with adverse reactions. Of the numerous factors that can favour the occurrence of these adverse drug reactions, the most important are the pathophysiological consequences of aging, particularly as these apply to the very old. Although absorption of drugs is not usually reduced in the elderly, diffusion, distribution and particularly elimination decline with age. Furthermore, while hepatic metabolic function is fairly normal, renal function is usually markedly depressed in very old individuals, and this can translate into clinical consequences if it is not taken into account. This is why, before administration of any drug in the elderly, evaluation of glomerular filtration rate is essential. Validated estimations such as those obtained from the classical Cockcroft-Gault formula or from more recent methodologies are required. In addition to reductions in various organ functions, factors connected with very old age such as frailty, falls, abnormal sensitivity to medications and polypathology, all of which tend to be more common in the last years of life, all directly impact on adverse drug reaction occurrence. Given these characteristics of the elderly population, the best way to reduce the prevalence of adverse drug reactions in this group is to limit drug prescription to essential medications, make sure that use of prescribed agents is clearly explained to the patient, give drugs for as short a period as possible, and periodically re-evaluate all use of drugs in the elderly.
引用
收藏
页码:375 / 392
页数:18
相关论文
共 50 条
  • [21] An Ensembled SVM Based Approach for Predicting Adverse Drug Reactions
    Joshi, Pratik
    Masilamani, V
    Ramesh, Raj
    CURRENT BIOINFORMATICS, 2021, 16 (03) : 422 - 432
  • [22] Factors predicting hospital readmissions related to adverse drug reactions
    Borja Ruiz
    Montserrat García
    Urko Aguirre
    Carmelo Aguirre
    European Journal of Clinical Pharmacology, 2008, 64 : 715 - 722
  • [23] Factors predicting hospital readmissions related to adverse drug reactions
    Ruiz, Borja
    Garcia, Montserrat
    Aguirre, Urko
    Aguirre, Carmelo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (07) : 715 - 722
  • [24] Adverse drug reactions in children: New perspectives on old problems
    Goldman, J.
    TOXICOLOGY LETTERS, 2016, 259 : S60 - S60
  • [25] PREVENTING ADVERSE DRUG EVENTS
    LEAPE, LL
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (04) : 379 - 382
  • [26] Preventing adverse drug events
    Davidson, Ann
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 176 (01) : 67 - 68
  • [27] Preventing an adverse drug event
    Goodman, LJ
    CRITICAL CARE MEDICINE, 1999, 27 (09) : 2027 - 2028
  • [28] PREVENTING DRUG REACTIONS
    不详
    MEDICAL JOURNAL OF AUSTRALIA, 1972, 1 (02) : 40 - &
  • [29] Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis
    Feng, Jihua
    Wu, Zimeng
    Yu, Qiao
    Li, Hongyuan
    Ji, Pan
    Yang, Yanli
    Zeng, Xiaoliang
    Zheng, Xiaowen
    Zhao, Chunling
    Zhang, Jianfeng
    EMERGENCY MEDICINE INTERNATIONAL, 2022, 2022
  • [30] Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in nonalcoholic steatohepatitis patients
    Solè?ne Marie
    Kayla L.Frost
    Raymond K.Hau
    Lucy Martinez-Guerrero
    Jailyn M.Izu
    Cassandra M.Myers
    Stephen H.Wright
    Nathan J.Cherrington
    Acta Pharmaceutica Sinica B, 2023, (01) : 1 - 28